SEARCH

SEARCH BY CITATION

References

  • 1
    Zimmermann AE. Tegaserod — A 5-HT4 agonist for women with constipation-predominant irritable bowel syndrome. Hosp Formulary 2002; 37: 449.
  • 2
    Degen L, Matzinger D, Merz M, et al. Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther 2001; 15: 174551.
  • 3
    Coffin B, Farmachidi JP, Rueegg P, Bastie A, Bouhassira D. Tegaserod, a 5-HT4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects. Aliment Pharmacol Ther 2003; 17: 57786.
  • 4
    Schoenfeld P, Chey WD, Drossman D, et al. Effectiveness and safety of tegaserod in treatment of irritable bowel syndrome: a meta-analysis of randomized controlled trials. Gastroenterology 2002; 122: A1486(Abstract).
  • 5
    Muller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT4 partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001; 15: 165566.
  • 6
    Novick J, Miner P, Krause R, et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002; 16: 187788.
  • 7
    Kellow J, Lee OY, Chang FY, et al. An Asia-Pacific, double-blind, placebo-controlled, randomised study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003; 52: 6716.
  • 8
    Cohen Munoz V. Relapse of symptoms following withdrawal of tegaserod treatment in irritable bowel syndrome with constipation (IBS-C) (Abstract). Gastroenterology 2003; 124: T1804.
  • 9
    Lin S, Zhou L, Xinguang L, et al. Tegaserod provides rapid, effective relief of abdominal pain/discomfort, bloating and constipation in Chinese patients with irritable bowel syndrome with constipation (Abstract). Gastroenterology 2003; 124: S1017.
  • 10
    Nyhlin H, Bang C, Elsborg L, et al. Tegaserod is an effective and safe therapy for irritable bowel syndrome in a Nordic population (Abstract). Gastroenterology 2003; 124: M1645.
  • 11
    Wald A, Johanson J, Tougas G, et al. Safety and tolerability of tegaserod in patients treated for chronic constipation (CC): a 12-week, double-blind, placebo-controlled multicenter study performed in the Americas (Abstract). Gastroenterology 2003; 124: T1818.
  • 12
    Talley N, Kamm M, Mueller-Lissner S, et al. Tegaserod is effective in relieving the multiple symptoms of constipation: results from a 12-week multinational study in patients with chronic constipation. Am J Gastroenterol 2003; 98: A810(Abstract).
  • 13
    Functional Dyspepsia Study D2201. Data on File. East Hanover: Novartis Pharmaceuticals Corporation, 2002.
  • 14
    Functional Dyspepsia Study D2202. Data on File. East Hanover: Novartis Pharmaceuticals Corporation, 2002.
  • 15
    Functional Dyspepsia Study D2203. Data on File. East Hanover: Novartis Pharmaceuticals Corporation, 2002.
  • 16
    Tack J, Delia T, Ligozio G, Sue S, Lefkowitz M, Vandeplassche L. A phase II placebo controlled randomized trial with tegaserod (T) in functional dyspepsia (FD) patients with normal gastric emptying (NGE). Gastroenterology 2002; 122: A154(Abstract).
  • 17
    Camilleri M. Review article: tegaserod. Aliment Pharmacol Ther 2001; 15: 27789.
  • 18
    Hasler WL, Schoenfeld P. Incidence of abdominal-pelvic surgery among patients with irritable bowel syndrome: a systematic review. Aliment Pharmacol Ther 2003; 17: 9971006.
  • 19
    Fisher R, Thistle J, Lembo A, et al. What is the impact of tegaserod on gallbladder emptying? Am J Gastroenterol 2003; 98: A813(Abstract).
  • 20
    Hasler W, Schoenfeld P. Safety profile of tegaserod, a 5-HT4 receptor agonist, for the treatment of irritable bowel syndrome. Drug Safety 2003 in press.